CIRSE 2017: BIOTRONIK Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the…
Physicians presented encouraging interim data on the efficacy of BIOTRONIK’s dedicated lower limb intervention portfolio…
Data Establishes Viability of BIOTRONIK Combination Therapy with Passeo-18 Lux Drug-Coated Balloon and Pulsar-18 Bare Me…
BIOTRONIK, a leader in cardio- and endovascular medical technology, today announced a partnership with Maquet Medical Sy…
Vielversprechende Zwischenergebnisse der Registerstudie BIOLUX P-III und neue Daten zur innovativen „Kombinationstherapi…
BIOTRONIK, a global leader in cardio- and endovascular medical technology, presented new data regarding the Passeo-18 Lu…
BIOTRONIK, a leader in cardio- and endovascular medical technology, announced today that it has received CE mark approva…
BIOTRONIK, ein führendes Gesundheitsunternehmen für kardiovaskuläre Medizintechnik, gab heute die CE-Zulassung für neue…
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, has presented the 24-month results fro…